C57BL/6JCya-Cdk7em1flox/Cya
Common Name:
Cdk7-flox
Product ID:
S-CKO-19329
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Cdk7-flox
Strain ID
CKOCMP-12572-Cdk7-B6J-VB
Gene Name
Product ID
S-CKO-19329
Gene Alias
C230069N13; CAK; Cdkn7; Crk4; P39 Mo15
Background
C57BL/6JCya
NCBI ID
Modification
Conditional knockout
Chromosome
13
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Cdk7em1flox/Cya mice (Catalog S-CKO-19329) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000091299
NCBI RefSeq
NM_009874
Target Region
Exon 4~5
Size of Effective Region
~2.4 kb
Detailed Document
Overview of Gene Research
Cdk7, or cyclin-dependent kinase 7, is a crucial protein. Along with cyclin H and MAT1, it forms the CDK-activating complex (CAK) that phosphorylates cell cycle CDKs for cell cycle progression. As a component of the general transcription factor TFIIH, Cdk7-mediated phosphorylation of RNA polymerase II at active gene promoters enables transcription [1,5].
In multiple myeloma, Cdk7 expression positively correlates with E2F and MYC transcriptional programs. Its inhibition counteracts E2F activity, impairs MYC-regulated metabolic gene signatures, and causes in vivo tumor regression [2].
In small cell lung cancer, inhibiting Cdk7 disrupts cell-cycle progression, induces DNA replication stress and genome instability, and triggers an immune-response signaling, providing a rationale for combination regimens with immunotherapies [4].
In esophageal squamous cell carcinoma, the CDK7-YAP-LDHD axis promotes D-lactate elimination and ferroptosis defense to support cancer stem cell-like properties [3].
In conclusion, Cdk7 is a key regulator in cell cycle and gene transcription. Its inhibition shows potential in treating various cancers including multiple myeloma, small cell lung cancer, and esophageal squamous cell carcinoma. Studies using in vivo models have revealed its roles in tumor-related biological processes, highlighting its significance as a therapeutic target in cancer research.
References：
1. Sava, Georgina P, Fan, Hailing, Coombes, R Charles, Buluwela, Lakjaya, Ali, Simak. . CDK7 inhibitors as anticancer drugs. In Cancer metastasis reviews, 39, 805-823. doi:10.1007/s10555-020-09885-8. https://pubmed.ncbi.nlm.nih.gov/32385714/
2. Yao, Yao, Ng, Jessica Fong, Park, Woojun Daniel, Munshi, Nikhil C, Fulciniti, Mariateresa. . CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. In Blood, 141, 2841-2852. doi:10.1182/blood.2022018885. https://pubmed.ncbi.nlm.nih.gov/36877894/
3. Lv, Mengzhu, Gong, Ying, Liu, Xuesong, Zhang, Weimin, Zhan, Qimin. 2023. CDK7-YAP-LDHD axis promotes D-lactate elimination and ferroptosis defense to support cancer stem cell-like properties. In Signal transduction and targeted therapy, 8, 302. doi:10.1038/s41392-023-01555-9. https://pubmed.ncbi.nlm.nih.gov/37582812/
4. Zhang, Hua, Christensen, Camilla L, Dries, Ruben, Gray, Nathanael S, Wong, Kwok-Kin. 2019. CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. In Cancer cell, 37, 37-54.e9. doi:10.1016/j.ccell.2019.11.003. https://pubmed.ncbi.nlm.nih.gov/31883968/
5. Fisher, Robert P. 2018. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery. In Transcription, 10, 47-56. doi:10.1080/21541264.2018.1553483. https://pubmed.ncbi.nlm.nih.gov/30488763/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen